ASCO Voices from China | Lijuan Chen: A Novel Highly Selective HDAC Inhibitor–Based Triplet Regimen Offers a New Strategy for Relapsed/Refractory Multiple Myeloma

ASCO Voices from China | Lijuan Chen: A Novel Highly Selective HDAC Inhibitor–Based Triplet Regimen Offers a New Strategy for Relapsed/Refractory Multiple Myeloma

The rapid emergence of CAR-T cell therapies and bispecific antibodies has transformed the treatment landscape for relapsed/refractory multiple myeloma (RRMM), leading to substantial improvements in patient outcomes. However, limitations related to accessibility, treatment costs, manufacturing complexity, and toxicity management continue to restrict their widespread use. As a result, there remains a pressing need for innovative therapies that combine efficacy, safety, and broad clinical applicability.
ASCO Voices from China | Huafeng Wang: Advancing Innovation and Expanding Possibilities—A Novel BCL-2 Inhibitor Brings New Hope for AML and MDS

ASCO Voices from China | Huafeng Wang: Advancing Innovation and Expanding Possibilities—A Novel BCL-2 Inhibitor Brings New Hope for AML and MDS

Despite significant advances in recent years, the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) continues to present major clinical challenges. Existing therapies offer limited efficacy for many patients, particularly those with high-risk disease, highlighting a substantial unmet medical need.
CGOG 2026 Day 2 | ASCO Neuroendocrine Tumors Highlights Session

CGOG 2026 Day 2 | ASCO Neuroendocrine Tumors Highlights Session

The 2026 Peking University Gastrointestinal Oncology Forum and the 16th CGOG Annual Meeting were held in Beijing from June 9–13, 2026. On June 10, the dedicated ASCO Neuroendocrine Tumors Highlights Session brought together leading Chinese experts to provide in-depth reviews of the latest advances in neuroendocrine tumor (NET) research presented at the 2026 ASCO Annual Meeting.
CGOG 2026 Day 3 | ASCO Highlights Session on Colorectal Cancer

CGOG 2026 Day 3 | ASCO Highlights Session on Colorectal Cancer

On June 11, Day 3 of the 16th Peking University Gastrointestinal Oncology Forum and CGOG Annual Meeting featured the 2026 ASCO Highlights Session on Colorectal Cancer, where leading experts provided in-depth reviews and discussions of the latest advances presented at the 2026 ASCO Annual Meeting. The session was livestreamed across multiple platforms and attracted more than 25,000 online viewers.
ASCO Highlights | Professor Yijun Shen: Dual Frontiers in Urologic Oncology Move Earlier as Chinese-Developed Immunotherapy Combinations Continue to Shine

ASCO Highlights | Professor Yijun Shen: Dual Frontiers in Urologic Oncology Move Earlier as Chinese-Developed Immunotherapy Combinations Continue to Shine

Chinese-developed immune checkpoint inhibitors, represented by toripalimab, are accelerating the transition of innovative therapies in urologic oncology from followers to global contributors. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Chinese innovation was not only featured in oral presentations but also prominently showcased in the poster halls. Toripalimab combined with 9MW2821 demonstrated promising bladder-preservation potential after moving from advanced disease into the perioperative setting. Immunotherapy plus chemotherapy expanded a uniquely Chinese approach to bladder preservation. Meanwhile, a phase III neoadjuvant trial of toripalimab combined with axitinib in renal cell carcinoma marked the first randomized evaluation of a targeted-immunotherapy combination moving from the frontline setting into neoadjuvant treatment. In this issue, Oncology Frontier invited Professor Yijun Shen from Fudan University Shanghai Cancer Center to discuss key poster presentations and share his perspectives on the evolving landscape of immunotherapy in urologic oncology at this year's ASCO meeting.
ASCO Voice of China | Prof. Yijun Shen Presents Oral Abstract on SHR-A2102 Combination Therapy: A New Breakthrough in Perioperative Treatment for MIBC

ASCO Voice of China | Prof. Yijun Shen Presents Oral Abstract on SHR-A2102 Combination Therapy: A New Breakthrough in Perioperative Treatment for MIBC

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting has once again brought together the latest breakthroughs in cancer research and drug development from around the world. As the largest and most influential oncology conference globally, every oral presentation represents a major advance in clinical practice and translational research.